Swiss pharma giant Roche said on Tuesday that a phase II clinical trial of its experimental obesity drug CT-388 had given positive results. +Get the most important news from Switzerland in your inbox In the study participants who received the active ingredient CT-388 once a week for 48 weeks lost over 20% of their body weight on average, Roche said in a press release on Monday. The higher the dose administered, the greater the weight loss. The effects were particularly clear at the highest dose tested. Almost all participants lost at least 5% of their body weight, around half even lost more than 20% and a quarter lost over 30%. Drug well tolerated According to Roche, the metabolism also benefited. Blood glucose levels normalised in almost three-quarters of the study participants with a preliminary stage of diabetes, significantly more than in the comparison group without the active ingredient. The drug was well tolerated overall. The most common side effects related to the ...
